What is NGNE's current stock price?

NGNE (Neurogene Inc.) is currently trading at $27.71 with a market cap of $437.9M.

What sector is Neurogene Inc. in?

Neurogene Inc. (NGNE) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NGNE a good stock to buy?

Analysts have a Buy consensus on NGNE with a price target of $69.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NGNE Neurogene Inc.

Healthcare

$27.71+0.36%ClosedMarket Cap: $437.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.60

P/S

0.00

EV/EBITDA

-3.21

DCF Value

$4.36

FCF Yield

-18.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-37.9%

ROA

-37.5%

ROIC

-44.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-30.9M	$—
Q4 null	$0.00	$-24.7M	$—
FY null	$0.00	$-90.4M	$—
Q3 null	$0.00	$-21.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$69.00

Target (Median)

$69.00

Target Range

$69.00 - $69.00

0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Canaccord GenuityBuy

2026-04-06

HC Wainwright & Co.Buy

2026-01-13

HC Wainwright & Co.Buy

2025-11-13

HC Wainwright & Co.Buy

2025-10-09

BMO CapitalOutperform

2025-06-12

Trading Activity

Insider Trades

View All

Cvijic Christine Mikaildirector, officer: President and CFO

SellFri May 08

Shafer Christinaofficer: Chief Commercial Officer

SellThu May 07

Shafer Christinaofficer

SellMon Apr 20

McMinn Racheldirector, officer: Chief Executive Officer

SellMon Mar 30

Jordan Julieofficer: Chief Medical Officer

SellMon Mar 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.08

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Peers

QSI